Dr. Dan Safarpour received a B.S. in Chemistry in 1991 from the University of Arkansas, Fayetteville and a Ph.D. in Environmental Analytical Chemistry in 2001 from Rutgers University, Cook College, New Brunswick, New Jersey. Dr. Dan Safarpour started his professional career as residue chemist atAltheimer Laboratory of the University of Arkansas in Fayetteville, Arkansas. In 1993, he began employment with American Cyanamid Company, Princeton, New Jersey as an Analytical Chemist in the Toxicology Analysis laboratory. Later, within Cyanamid Global Research Center, he moved to other research group called Metabolism, Residue, Environmental Fate and Eco-Toxicology (MREE) Group as a Residue Chemist/Study Director. In 2000, American Cyanamid Company was acquired by BASF Corporation, at which time he joined the Formulations Analysis Group. In September 2001, he joined Taxolog, Inc, a pharmaceutical/biotechnology startup company. As a group leader at Taxolog, he was brought on-board to build an analytical group capable of conducting formulations analysis support as well as metabolism and bioanalytical to determine metabolite structures to protect company IP on pharmaceutically active metabolites and co-drugs. Dr. Safarpour led his team in compiling analytical R&D and dossier preparation for filing several IND, CTX and aNDA in partnership with Pfizer corporation. Dr. Safarpour has been published in journals such as Journal of Pharmaceutical and Biomedical Analysis (JPBA), Journal of Chromatography, Electrophoresis, Journal of Associations of Officials in Analytical Chemistry (JAOAC) and Journal of Pesticide Science. Per invitation from US-EPA regulatory bodies, Dr. Safarpour has contributed a chapter on Application of Capillary Electrophoresis to Pesticide Analysis to the Encyclopedia of Agrochemicals. Dr. Safarpour has given numerous oral presentations in national and international conferences in the areas of separation sciences, process and formulations analysis, human and plant metabolism, bioanalytical, and residue chemistry. His presentations have focused on the use of cutting-edge technologies such as UPLC, HPLC, CE, and GC, as well as UPLC-MS-QTOF, HPLC-MS-Triple Quad platforms and CE-MS. Dr. Safarpour has chaired symposium in peptide-protein friendly instrumentations arena, judged poster presentations at ACS functions such as the Triangle Chromatography Discussion Group (TCDG). Since 2003 until 2015, Dr. Safarpour has served on the peer review committee for prestigious journals such as JPBA, JAOAC and Electrophoresis. In early 2009, Dr. Safarpour, with former colleagues, employees founded a new life sciences contract research organization called Symbiotic Research, LLC. In 2017, he sold Symbiotic Research to a German conglomerate-Tentamus GmbH. In 2018, together with Tentamus GmbH, Dr. Safarpour acquired animal research facility Genesis Midwest, LLC out of Wisconsin USA to enable Symbiotic Research to provide in-life and analytical package study services to its global Animal Health and Agrochemical clients. In 2014, Dr. Safarpour was hired by International Atomic Energy Agency (IAEA) Food Safety division as an “Expert Lecturer” to consult the agency by traveling to developing countries and guiding the subject nations on matters related to building laboratories and laboratory infrastructures capable of analyzing agricultural food products by LCMS and ultimately helping those nations to be able to export their raw agricultural products globally in an attempt to expand their GDP growth and aid in global food sustainability.

John A. Cidlowski, Ph.D., heads the Molecular Endocrinology Group within the Laboratory of Signal Transduction (LST), and is Chief of the LST. He received his Ph.D. in 1975 from Medical College of Georgia in Endocrinology. He has published over 300 peer-reviewed articles in leading biomedical journals, as well as several book chapters. He served as Professor of Physiology and Biochemistry at University of North Carolina at Chapel Hill before joining the NIEHS in 1995.

Graeme has over 25 years of experience in the Pharmaceutical Industry and maintains strong operational oversight within the company. Before creating the PharSafer and SaPhar brands, Graeme was Head of Global Drug Safety for a multi-national Pharmaceutical Company and EU Qualified Person for Pharmacovigilance (EU QP PV). During his long career in Drug Safety and Medical Services, Graeme has partnered with a global safety database provider to design a validated global medical information database, which is linked directly to the safety database.
As an international voice of authority in Pharmacovigilance, Graeme has written a modular book series on Multi-National Pharmacovigilance (2006, 2010) and has written many articles on Pharmacovigilance in peer-reviewed journals. Graeme currently serves as Editor of a multi-national Pharmacovigilance journal and is a regular speaker at industry conferences, in addition to being an active member of many international associations which include the DIA, TOPRA, ISOP and SIAC.

Dr. Prokai-Tatrai is presently working as a Professor of Pharmacology & Neuroscience and Pharmaceutical Sciences at UNT System College of Pharmacy, University of North Texas Health Science Center, USA. She received her Ph.D. in Organic Chemistry, M.Sc. in Chemistry and B.Sc. in Chemical Engineering from University of Pannonia, Hungary. She completed her NIH Postdoctoral Fellow in Medicinal Chemistry/Drug Delivery and Bioanalytical Chemistry, University of Florida, Florida. She is an award-winning researcher and pharmacy educator at UNTHSC. She has six issued US patents. She received many awards including “Hero of the Week” (2014) rewarded by the UNTHSC Cabinet and First Faculty Excellence Award (2017) for the UNT System College of Pharmacy. She has published articles in peer-reviewed journals. She has participated in various international and national conferences and gave presentations. She serves as a member of various national committees UNTHSC Faculty Bylaws and Policies Committee and Interviewer, Texas College of Osteopathic Medicine. She serves as an editorial board member of numerous journals and an academic editor of a successful special issue on neuroprotection. Dr. Prokai-Tatrai’s research Interest is in Medicinal chemistry-based drug design and delivery into the central nervous system using prodrug approaches, Neuroprotection based on estrogens, GC/LC-MS-based bioanalytical assay development, and Mass spectrometry-based proteomics.

Dr. Subhash C. Basak is an Adjunct Professor at the Department of Chemistry and Biochemistry, University of Minnesota Duluth, USA. Dr. Basak received his PhD degree in biochemistry from the University of Calcutta, India. During the past four decades he has pioneered research in the development of novel mathematical chemodescriptors and biodescriptors principally via applications of discrete mathematics on chemical and biological systems. He also published extensively on the use of such descriptors along with proper statistical methods in drug design, predictive toxicology, characterization of emerging global pathogens as well as nanotoxicology.He has collaborated with over fifty research scientists located in four continents, viz., Asia, Europe, North America, and South America, whom he fondly calls members of his “virtual team”. Such collaborations resulted in the publication of more than 300 journal papers, 35 book chapters, and review article.

Dr. Naoual Oukkache leads the Venoms and Toxins Laboratory at the Pasteur Institute of Morocco. Driven by passion, Naoual excels in animal venoms and antivenoms focusing on proteomics, pharmacology, antibody engineering and preclinical studies.
She trained and collaborates with several institutes including Marseille University of Medicine, Butantan Institute, Cuernavaca Biotechnology Institute, Kuala Lumpur Monash University; as well as the Albila, Atheris and Bioclon companies. Naoual currently participates in clinical studies and develops innovative antivenoms.
Dr. Oukkache co–authored +30 publications, is editorial board member of journals, a member of scientific committees and societies, coordinates international grants and supervises Masters and PhD students.

Anthony William completed his MSc and Postgraduate studies in Pharmaceutical and Biomedical Sciences at the age of 30 years from the Faculty of Pharmacy, university of Lyon. He is one of the most famous and reputed g as an Editorial Board Member of great repute pharmacists, researchers and scientists. His new researches focused on the synthesis, discovery, and development of new drugs and medicines for the most resistant and untreated human diseases. He is the head of pharmacists at the university of Lyon.

Dr Omri is currently Full Professor in the Department of Chemistry and Biochemistry with a cross appointment to the Department of Biology, the Biomolecular Sciences PhD Programme, School of Rural and Northern Health PhD Programme. Dr. Omri is also involved in the education of undergraduate and graduate students through the coordination of several calendar courses in biochemistry, pharmacology and toxicology and pharmaceutical technology.
Dr. Omri is actively involved in the research training of both undergraduate and graduate students. Dr. Omri has served in administrative capacities in several international scientific societies. He has published over 50 peer-reviewed research articles over his career on various aspects of drug delivery and targeting in addition to several published book chapters and books (2). He has served on a number of Editorial Boards and Granting Agencies in Canada and abroad. He has 2 patents.

Sanjay Gupta has authored some 130 publications, including book chapters, research articles and reviews, and has spoken at several occasions in cancer prevention symposium, seminars and meetings. He has obtained funding from National Cancer Institute (NCI), National Center for Complementary and Alternative Medicine (NCCAM) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He has also received his funding support from various private foundations including Cancer Prevention Foundation, Ohio Board of Reagents and The Gateway for Cancer Research. He has been serving in various study sections at NCI and Department of Defense (DOD) and reviewer for several prestigious scientific journals. His innovative research on basic and translational aspects has led to publications in several peer-reviewed high-impact scientific journals including Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Sciences, USA, Journal of Clinical Oncology, FASEB Journal and has been featured on NBC-5 news and highlighted in the Plain Dealer, and American Association for Cancer Research press release

Dr. Nagasamy Venkatesh is working as Assistant Professor at Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam. India. Dr. D.Nagasamy Venkatesh is interested in developing certain nanobased drug delivery systems for antiviral and anticancer drugs. His research is also extended in developing oral sustained/controlled drug delivery systems for certain drugs of therapeutic interest and analytical and bio-analytical method development for such drugs. He serves as a reviewer of more than 25 peer reviewed journals including AAPS, Carbohydrate polymer, Indian Journal of Pharmaceutical Sciences. He has authored more than 50 peer-reviewed publications. He has received three best awards for his presentations/publications in national and international level conferences. Research Interest: Nano based drug delivery systems for antiviral and anticancer drugs, developing sustained/controlled drug delivery systems for certain drugs and dissolution enhancement of certain drugs by solid dispersion techniques.